Hanmi Pharm. Co., Ltd. (128940.KS) Stock
Hanmi Pharm. Co., Ltd.

Company profile
Hanmi Pharm. reported revenue of 1.50 trillion KRW for fiscal year 2024, up 0.3% from fiscal year 2023, and net income of 121.32 billion KRW. That is a net profit margin of 8.1% for fiscal year 2024. In Q3 2025 (the quarter ended September 30, 2025) revenue was 362.35 billion KRW, up 0.1% from a year before. Its largest business segment, Medicine, brought in 70% of segment revenue in fiscal year 2025; Republic of Korea was the largest region with 61%. In Q3 2025 it reported net income of 40.13 billion KRW, against net income of 31.00 billion KRW a year earlier. Our analysis of its filings shows revenue growing from 1.33 trillion KRW in fiscal year 2022 to 1.50 trillion KRW in fiscal year 2024, 6.0% a year on average. Hanmi Pharm. reports about 2,498 full-time employees.
What stands out
- Revenue in fiscal year 2024 was the highest of the last 5 fiscal years.
Figures from company filings; latest fiscal year ended December 31, 2024.
About Hanmi Pharm. Co., Ltd.
Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company's products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company has a research collaboration with MEDIC Life Sciences Inc. to identify cancer biomarkers. The company was founded in 1973 and is based in Hwaseong-si, South Korea.
Largest shareholders
- Hanmi Science Co., Ltd.41.42%
- National Pension Service of Korea10.98%
- Dong-Guk Shin7.717 %7.72%
- Hanmi Pharm. Co., Ltd.1.02%
- Pecotek Co., Ltd.0.95%
Share of the company, as of May 18, 2026
Leadership
- Jae-Hyun Park — CEO & Director, 57
- Jong-Hoon Lim — Executive Director & Management Planning /CIO, 48
- Chang-Ju Choi — Vice President of Information Management Team
In the news
- Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC
- Short Bowel Syndrome Market to Register Stunning Growth at a CAGR of 5% During the Forecast Period (2025-2034) Owing to the Launch of Novel GLP-2 Analogues | DelveInsight
- Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical
- Health Hope Pharma Enters into Exclusive Licensing Agreement with Gilead Sciences
How much revenue does Hanmi Pharm. make?
Hanmi Pharm. reported 1.50 trillion KRW in revenue for fiscal year 2024, up 0.3% from 1.49 trillion KRW in fiscal year 2023. In Q3 2025 revenue was 362.35 billion KRW.
What is Hanmi Pharm.'s largest business segment?
Medicine, with 1.15 trillion KRW or 70% of segment revenue in fiscal year 2025. Next: Overseas Medicine (25%) and Raw Drug Substance (6%).
Where does Hanmi Pharm. make most of its revenue?
Republic of Korea: 61% of revenue by region in fiscal year 2025, followed by China (26%).
What companies are similar to Hanmi Pharm.?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Alteogen Inc. (196170.KQ), Yuhan Corporation (000100.KS), Hanall Biopharma Co., Ltd. (009420.KS), LigaChem Biosciences Inc. (141080.KQ).
How has Hanmi Pharm.'s revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2020, 1.08 trillion KRW; FY2021, 1.20 trillion KRW; FY2022, 1.33 trillion KRW; FY2023, 1.49 trillion KRW; FY2024, 1.50 trillion KRW.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Hanmi Pharm. Co., Ltd. (128940.KS)”, data as of May 18, 2026, https://dataporium.tech/stocks/128940.KS